At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Active Treatment- CT1812 100 mg +2 moredrug
Likely dose
Active Treatment- CT1812 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, and 1 other intervention for Alzheimer Disease. Completed, enrolled 43 participants across 1 site.
Detailed Summary
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionOct 2020
TodayJul 2026
First PostedApr 10, 2018
Enrollment StartMar 28, 2018
Primary CompletionOct 16, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.2 years ago
Interventions
Active Treatment- CT1812 100 mgdrug
CT1812
Active Treatment- CT1812 300 mgdrug
CT1812
Placebodrug
Matching Placebo